GLSI
Greenwich LifeSciences, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 22 Greenwich LifeSciences announced a Nasdaq non-compliance notice due…
- R May 22 Greenwich LifeSciences reported Q3 2025 EPS of -$0.30, beating conse…
- B Jul 23 to Jul 29 5 days of insider buys: $97.0K by 1 insider, avg $13.29
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $97.0K at an average $13.29. No open-market sales. Price is 29% above their cost.
- InstitutionsBULLISH
Q2 2026: 8 added (0 new), 2 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$0.335 → −$0.335 over 90 days.
- TrendRANGE
3% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $1.9M |
| MORGAN STANLEY | ADD | $1.0M |
| STRS OHIO | ADD | $417.6K |
| WELLS FARGO & COMPANY/MN | DOUBLED | $144.1K |
| CITIGROUP INC | DOUBLED | $74.9K |
| BARCLAYS PLC | TRIM | $19.9K |
| Legal & General Group Plc | ADD | $18.5K |
| ROYAL BANK OF CANADA | DOUBLED | $8.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2026Price is below the lowest target. Median implies +233%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 29, 2026 | Patel Snehal CEO and CFO | BUY | $9.2K |
| Jul 28, 2026 | Patel Snehal CEO and CFO | BUY | $20.4K |
| Jul 27, 2026 | Patel Snehal CEO and CFO | BUY | $20.4K |
| Jul 24, 2026 | Patel Snehal CEO and CFO | BUY | $14.2K |
| Jul 23, 2026 | Patel Snehal CEO and CFO | BUY | $32.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.34 | -$0.37–-$0.30 | +9.5% | $0.00 |
| Next Q | -$0.35 | -$0.40–-$0.30 | +12.5% | $0.00 |
| Current FY | -$1.39 | -$1.48–-$1.29 | +6.4% | $0.00 |
| Next FY | -$1.17 | -$1.17–-$1.17 | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
6 filings · 1 press release · 2 bullish · 2 bearish · 2 neutral- NEUTRAL DEFA14AOct 26, 2026
Greenwich LifeSciences filed a DEFA14A (additional definitive proxy soliciting materials) on the same day as its definitive proxy statement (DEF 14A). The filing contains no substantive new information beyond the routine proxy proposals for the 2026 annual meeting: election of five incumbent…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL DEF 14AOct 26, 2026
Greenwich LifeSciences filed its definitive proxy statement for the 2026 annual meeting. The filing is routine: it proposes the election of five incumbent directors, ratification of MaloneBailey as auditor, and advisory votes on executive compensation and frequency.
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASEAug 10, 2026
Greenwich LifeSciences extended its insider and pre-IPO investor lock-up to January 31, 2027…
Traders should view the lock-up extension as a positive insider confidence signal that reduces near-term overhang. Monitor for any early termination of the lock-up or announcements of strategic…
- BULLISH INSIDER-BUYJul 30, 2026
Greenwich LifeSciences CEO/CFO Snehal Patel purchased $88K of GLSI shares on the open market over…
The CEO/CFO's concentrated buying over a short window suggests management sees value at current levels. Monitor for upcoming clinical or regulatory catalysts (e.g., FDA updates on GP2 vaccine trial)…
All GLSI filing & press-release reports (7)
- DEFA14A reportOct 26, 2026
- DEF 14A reportOct 26, 2026
- PRESS-RELEASE reportAug 10, 2026
- INSIDER-BUY reportJul 30, 2026
- INSIDER-BUY reportJul 29, 2026
- PRESS-RELEASE reportMay 22, 2026
- PRESS-RELEASE reportApr 22, 2026